← FDA DRUG APPROVALS

FDA ANDA · ANDA065002

CEFUROXIME SODIUM

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA065002
TYPE
ANDA
ORIGINAL APPROVAL
1998-09-28
LATEST ACTION
2009-09-29
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CEFUROXIME SODIUMDiscontinued
CEFUROXIME SODIUM EQ 7.5GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2009-09-29Labeling · Supplement 7AP
2008-03-31Labeling · Supplement 6AP
2004-02-20Labeling · Supplement 4AP
2003-04-30Labeling · Supplement 3AP
2002-10-10Labeling · Supplement 2AP
2002-03-28Manufacturing (CMC) · Supplement 1AP
1998-09-28OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →